Gara Jalqabaatti › Kansa Endometiriyaalii › Oregon
Qorannoo klinikaalii Kansa Endometiriyaalii Oregon keessatti
Qorannoo 27 Kansa Endometiriyaalii f Oregon keessatti hirmaatuu jiru.
Magaalota Oregon keessatti
Takkalaa qorannoo (Ingiliffa)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 05-Onk-2026 · NCT07198074Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin hundi · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05564377Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 130 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05797168The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Oregon Health & Science University (OHSU), Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 02, Portland
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07814248Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05867251Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 28-Ful-2026 · NCT05112601Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Portland
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06218914Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Providence Portland Medical Centre, Portland
- Providence Saint Vincent Medical Center, Portland
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 24-Ful-2026 · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Oncology Associates of Oregon, P.C. ( Site 8005), Eugene
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 17-Ful-2026 · NCT06952504Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Providence Portland Medical Center, Portland
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
- NW Cancer Specs. P.C., Happy Valley
- USOR - NW Cancer Specs P.C., Portland
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 09-Ful-2026 · NCT07166094A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Providence Cancer Institute of Oregon, Portland
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Eugene
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 03-Ful-2026 · NCT06989112FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Oregon Health and Science University, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT05919264A Study of MGC026 in Participants With Advanced Solid Tumors
- Providence Cancer Institute, Portland
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT06242470Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Oncology Associates of Oregon, P.C., Eugene
- Compass Oncology - Rose Quarter, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oregon Health & Science University, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Eugene
- Research Site, Portland
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 29-Ado-2026 · NCT07044336Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #121, Portland
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ado-2026 · NCT06974110Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 517, Eugene
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 16-Ado-2026 · NCT06906341First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Providence Cancer Institute Franz Clinic, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ado-2026 · NCT05768139cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 fi ol · Saalaa hunda · Haaromfame 20-Ama-2026 · NCT05366881Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Oncology Associates of Oregon, P.C., Eugene
- Northwest Cancer Specialists, P.C., Portland
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 24-Mud-2025 · NCT06463028SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Portland
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Oregon Health & Science University, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Gur-2025 · NCT05669430Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Oncology Associates of Oregon, Eugene
- Northwest Cancer Specialists, Portland
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Dubartoota · Haaromfame 02-Cam-2024 · NCT05797831Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.